Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858455 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00858455 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT00858455, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose is to study the effect of Maalox® and One A Day® on the pharmacokinetics of GSK1349572, and also to compare the safety of GSK1349572 when administered alone and when administered with Maalox® and One A Day®. There are four dosing periods in this study, each period requires a 4 night stay. A follow-up visit is also required at approximately 7 days after the last dose administration. Starting from the first period to the follow-up, it will take about 1 month. Screening visit is required to be completed within 30 days prior to the first dose. MAALOX® is a registered trademark of Novartic Consumer Health, LLC. ONE A DAY® is a registered trademark of Bayer Healthcare LLC.
Interventions
- DRUG GSK1349572
- DRUG GSK1349572 and MaaloxAdvanced Maximum Strength
- DRUG GSK1349572 and Maalox Advanced Maximum Strength
- DRUG GSK1349572 and One A Day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858455
The ClinicalTrials.gov registry entry for NCT00858455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GSK1349572 is the first listed.
NCT00858455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858455 about?
NCT00858455 is a clinical study titled "A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572". The purpose is to study the effect of Maalox® and One A Day® on the pharmacokinetics of GSK1349572, and also to compare the safety of GSK1349572 when administered alone and when administered with Maalox® and One A Day®. There are four dosing periods in this study, each period requires a 4 night stay...
What is the current status of trial NCT00858455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00858455?
The interventions under investigation include: GSK1349572 (DRUG), GSK1349572 and MaaloxAdvanced Maximum Strength (DRUG), GSK1349572 and Maalox Advanced Maximum Strength (DRUG), GSK1349572 and One A Day (DRUG).
Who is sponsoring clinical trial NCT00858455?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.